Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NeueHealth's Enterprise Value for the quarter that ended in Jun. 2025 was $1,106.3 Mil.
NeueHealth's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeueHealth EV-to-EBIT Related Terms
NeueHealth EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for NeueHealth's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, NeueHealth's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeueHealth EV-to-EBIT vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, NeueHealth's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NeueHealth's EV-to-EBIT falls into.
NeueHealth's current Enterprise Value is $1,105.0 Mil.
NeueHealth's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeueHealth (NEUE) has a EV-to-EBIT of -30.95 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NeueHealth and its competitors.
Is NeueHealth's EV-to-EBIT too high?
NeueHealth's current EV-to-EBIT is -30.95. Overall, NeueHealth has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does NeueHealth's EV-to-EBIT compare to PFHO and UNH?
NeueHealth's EV-to-EBIT of -30.95 can be compared against companies in the Healthcare Plans industry. The industry median EV-to-EBIT is 19.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Plans company?
The median EV-to-EBIT among Healthcare Plans companies is 19.38, based on 15 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NeueHealth and its competitors. For the Healthcare Plans industry, the median EV-to-EBIT is 19.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeueHealth's current EV-to-EBIT is -30.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeueHealth stock overvalued right now?
NeueHealth (NEUE) has a current EV-to-EBIT of -30.95. The current EV-to-EBIT is -30.95. NeueHealth's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NeueHealth (NEUE), the current EV-to-EBIT is -30.95 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.
20GF Score
Get the complete analysis for NEUE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUE has been successfully added to your 
